AOD-9604 vs Tesamorelin
How they differ
- FDA status. AOD-9604: Not FDA-approved; FDA advised against adding it to the compounding list.1,2,3 Tesamorelin: FDA-approved as Egrifta for HIV-associated abdominal fat.4,5
- Kinds of studies cited. AOD-9604: limited human data. Tesamorelin: large randomized human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | AOD-9604 | Tesamorelin |
|---|---|---|
| What it is | A synthetic 16-amino-acid fragment of human growth hormone (residues 177 to 191 plus an added tyrosine), according to FDA’s 2024 evaluation.1 | A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.4 |
| FDA status | Not FDA-approved Not FDA-approved; FDA advised against adding it to the compounding list1,2,3 Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,3 | FDA-approved FDA-approved as Egrifta for HIV-associated abdominal fat4,5 FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.4,5 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.6 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. AOD-9604 is not among them.6,7 | Not among the six peptides the policy lists.6 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists AOD-9604 among substances whose nominations were withdrawn, citing possible immune reactions, characterization problems and serious adverse events of unclear cause.3 | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 11 ClinicalTrials.gov records and 21 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 2December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 5Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026